Silver Book Fact

Life expectancy and quality of life gains from AVR

A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years gained at a net value of $11.2 billion (~$14.2 billion in 2017 dollars).

Wu Y, Grunkmeier G, Starr A. The Value of Aortic Valve Replacement in Elderly Patients: An economic analysis. Journal of Thoracic and Cardiovascular Surgery. 2007; 133(3): 603-7. http://www.jtcvsonline.org/article/S0022-5223(06)01477-2/fulltext

Reference

Title
The Value of Aortic Valve Replacement in Elderly Patients: An economic analysis
Publication
Journal of Thoracic and Cardiovascular Surgery
Publication Date
2007
Authors
Wu Y, Grunkmeier G, Starr A
Volume & Issue
Volume 133, Issue 3
Pages
603-7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states